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 Rare loss-of-function variants in SETD1A are associated  with 
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Jaana Suvisaari7, Himanshu Chheda2, Douglas Blackwood8, Gerome Breen9,10, Olli Pietiläinen1,2,7,   
Sebastian S Gerety1, Muhammad Ayub11, Moira Blyth12, Trevor Cole13, David Collier14,15, Eve L 
Coomber1,  Nick Craddock16, Mark J Daly3,17, John Danesh1,18,19, Marta DiForti9, Alison Foster20, 
Nelson B Freimer21, Daniel Geschwind22, Mandy Johnstone8, Shelagh Joss23, Georg Kirov16, Jarmo 
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Lönnqvist7, Minna Männikkö27,   Steve A McCarroll17,28, Peter McGuffin9, Andrew M McIntosh8, 
Andrew McQuillin29, Jukka S Moilanen25, Carmel Moore18,19, Robin M Murray9,10, Ruth 
Newbury-Ecob30, Willem Ouwehand1,18,31,32, Tiina Paunio33,34, Elena Prigmore1, Elliott Rees16, 
David Roberts18,35,36, Jennifer Sambrook19,31, Pamela Sklar5, David St Clair37, Juha Veijola38, 
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By analyzing the whole-exome sequences of 4,264 schizophrenia cases, 9,343 controls and 1,077 
trios, we identified a genome-wide significant association between rare loss-of-function (LoF) 
variants in SETD1A and risk for schizophrenia (P = 3.3 × 10−9).  We found only two heterozygous LoF 
variants in 45,376 exomes from individuals without a neuropsychiatric diagnosis, indicating that 
SETD1A is substantially depleted of LoF variants in the general population. Seven of the ten 
individuals with schizophrenia carrying SETD1A LoF variants also had learning difficulties. We further 
identified four SETD1A LoF carriers among 4,281 children with severe developmental disorders and 
two more carriers in an independent sample of 5,720 Finnish exomes, both with notable 
neuropsychiatric phenotypes. Together, our observations indicate that LoF variants in SETD1A cause 
a range of neurodevelopmental disorders, including schizophrenia. Combining these data with 
previous common variant evidence, we suggest that epigenetic dysregulation, specifically in the 
histone H3K4 methylation pathway, is an important mechanism in the pathogenesis of 
schizophrenia. 
Schizophrenia is a common, debilitating psychiatric disorder that is characterized by positive 
symptoms (hallucinations, delusions and disorganization) and negative symptoms (impaired 
motivation, reduced spontaneous speech and social withdrawal). It is associated with cognitive 
impairment, decreased social and occupational functioning, and increased mortality, with a 12–15-
year reduction in lifespan1–3. Schizophrenia has a lifetime risk of ~0.7% and a substantial genetic 
component, with a sibling recurrence risk ratio of 9.0 and an estimated heritability of up to 81% 
(refs. 4,5). 
The genetic architecture of schizophrenia involves a combination of common, rare and de novo risk 
variants. At one end of this spectrum, a genome-wide association study of 36,989 cases identified 
108 loci containing alleles of individually small effect (median odds ratio = 1.08)6,  whereas, at the 
other, at least 11 rare, recurrent copy number variants (CNVs) (for example, at chromosomes 
1q21.1, 15q13.3 and 22q11.2) individually confer substantial risk for schizophrenia (ORs 2–60)7–10. 
A recent case-control exome sequencing study demonstrated a burden of rare disruptive variants 
across a set of 2,546 genes selected on the basis of a variety of biological hypotheses about 
schizophrenia risk and previous genome-wide screens, including GWAS, CNV and de novo mutation 
studies11. This study did not, however, identify any individual schizophrenia risk genes at a 
Bonferroni P value of 1.25 × 10−6 (Online Methods). Parent-proband trio studies have sought to 
increase power by focusing on de novo mutations: the rarity of damaging events makes it possible to 
observe statistically significant recurrence of mutations in individual genes with smaller sample sizes 
than would be required in a case-control design. Three such studies in schizophrenia have found 
suggestive evidence for candidate genes, including EHMT1, DLG2, TAF13 and SETD1A9,12,13. The 
statistical significance of de novo recurrence is highly dependent on the specification of gene-
specific mutation rates, which are difficult to calibrate for indels and CNVs (Online Methods). 
Because these genes are supported by two de novo events each, of which all but one (in TAF13) are 
either an indel or CNV, further evidence is needed to firmly establish these as susceptibility genes. 
A R T I C L E S 
Two insights have emerged from these early results in schizophrenia. First, genetic risk loci have 
implicated general biological processes involved in pathogenesis, including histone methylation 
(common variants)14, transmission at glutamatergic synapses and translational regulation by the 
fragile X mental retardation protein (rare and  de novo variants)11,12. Second, studies of common 
and rare variation support a highly polygenic architecture involving hundreds of genes, suggesting 
that very large sample sizes will be required to convincingly identify individual risk genes. This 
polygenicity is reminiscent of other neuropsychiatric disorders, such as autism spectrum disorder 
(ASD), which required many thousands of exome sequences and the integration of de novo 
mutations with case-control burden of rare variants to identify genes at genome-wide 
significance15,16. 
RESULTS 
Case-control analysis of schizophrenia exomes 
We sequenced the exomes of 1,887 (1,488 UK and 399 Finnish) individuals with schizophrenia and 
7,585 (5,469 UK and 2,116 Finnish) individuals without a known neuropsychiatric diagnosis. We 
jointly called each case set with its nationality-matched controls, but still observed substantial batch 
effects from the use of different exome capture reagents used at different time points in the 
experiment (Supplementary Fig. 1). We therefore performed careful quality control (QC) in each set 
to narrow our analysis to regions with high-quality data in all samples and to remove outlier samples 
and variants (Online Methods and Supplementary Fig. 2), leaving a total of 1,745 cases and 6,789 
controls (Fig. 1). To increase power for gene discovery, we combined our data set with exome 
sequences of 2,519 Swedish schizophrenia cases and 2,554 controls from a previous study11. The 
average number of coding SNPs and indels varied among these three sample sets as a result of 
differences in exome capture technology, QC procedures and sample ancestry, but were closely 
matched between cases and controls in each set (Supplementary Figs. 3–5). We restricted our 
analyses to rare variants, stratified by allele frequency (singletons, <0.1%, and <0.5%) and function 
(LoF and damaging missense variants; Online Methods). In total, this joint discovery set consisted of 
357,088 damaging missense and 55,955 LoF variants called in 4,264 cases and 9,343 controls (Fig. 1). 
We replicated the enrichment of rare LoF variants in the previously implicated set of 2,456 genes11 
in our UK and Finnish schizophrenia data sets (P = 7 × 10−4; Online Methods). Having confirmed that 
rare disruptive variants spread among many genes are associated with schizophrenia risk, we tested 
for an excess of disruptive variants in each of 18,271 genes in cases compared with controls (Online 
Methods). Despite our sample size, the per-gene statistics followed a null distribution in all tests, 
and we were unable to implicate any gene via case-control burden of disruptive variants 
(Supplementary Figs. 6 and 7). 
LoF variants in SETD1A are associated with schizophrenia To determine whether the integration of 
de novo mutations with case-control burden might succeed in discovering risk genes in 
schizophrenia, we aggregated, processed and re-annotated de novo mutations in 1,077 
schizophrenia probands from seven published studies, and found 118 LoF and 662 missense 
variants12,13,17–21 (Supplementary Table 1). 38 genes had two or more de novo nonsynonymous 
mutations, two of which (SETD1A and TAF13) had been previously suggested as candidate schiz-
ophrenia genes12,13. We found that the 754 genes with de novo mutations were significantly 
enriched in rare LoF variants in cases compared with controls from our main data set. The most 
significant enrichment across allele frequency thresholds and functional class was for the test of LoF 
 variants with MAF < 0.1% (P = 2.1 × 10−4; OR 1.08, 95% confidence interval (CI) 1.02–1.14), which we 
focused on for subsequent analysis. 
Motivated by this overlap of genes with de novo mutations and excess case-control burden, we 
metaanalyzed de novo variants in the 1,077 published schizophrenia trios with rare LoF variants 
(MAF < 0.1%) in 4,264 cases and 9,343 controls. We used two analytical approaches, one based on 
Fisher’s method to combine de novo and case-control P values, and the other using the transmission 
and de novo association (TADA) model to integrate de novo, transmitted and case-control variation 
using a hierarchical Bayesian framework15,22 (Fig. 1). We focused on results that were significant in 
both analyses and that did not depend on the choice of parameters in TADA (Online Methods and 
Supplementary Fig. 8). In both methods, loss-of-function mutations in a single gene, SETD1A, were 
significantly associated with schizophrenia risk (Fisher’s combined P = 3.3 × 10−9; Table 1). We 
observed three de novo mutations and seven case LoF variants in our discovery cohort and none in 
our controls (Fig. 2). In one of the seven case carriers, direct genotyping in parents confirmed that 
the LoF variant (c.518-2A>G) was a de novo event, but genotypes were not available for the other 
parents. We looked for additional SETD1A LoF variants in unpublished whole exomes from 2,435 
unrelated schizophrenia cases and 3,685 controls23, but found none (Table 1). Thus, in more than 
20,000 exomes, we observed ten case and zero control LoF variants (corrected OR 35.2, 95% CI 4.5–
4,528). Although the confidence inter-vals were wide, rare LoF variants in SETD1A conferred 
substantial risk for schizophrenia. No other gene approached genome-wide significance 
(Supplementary Table 2 and Supplementary Figs. 9 and 10). 
Robustness of the SETD1A association 
To validate our observation of the rarity of disruptive variants in SETD1A in unaffected individuals, 
we examined the exomes of 45,376 individuals without schizophrenia in the Exome Aggregation 
 
Consortium (ExAC) database and found only 2 LoF variants24, which represented a substantial 
depletion compared with chance expectation (Online Methods, expected value 32.5 LoF SNPs,  P = 
4.4 × 10−8). SETD1A is among the 3% most constrained genes in the human genome24; LoF variants 
in SETD1A are almost totally absent in the general population. Four of the ten SETD1A carriers with 
schizophrenia had the same two-base deletion at the exon 16 splice acceptor (c.4582-2delAG>-), at 
least two of which occurred as de novo mutations (Fig. 2). Given that this variant underpinned the 
statistical significance of our observation, we investigated it further in several ways. First, to rule out 
sequencing artifacts, we confirmed a clean call where we had access to the raw sequencing reads (n 
= 2) and noted that both published de novo mutations at this position had been validated with 
Sanger sequencing13,20. Second, our model, and therefore the test statistic that we report, is 
dependent on a gene-specific mutation rate (Online Methods). To address the possibility that the 
recurrent mutation occurs at a hypermutable site (and thus our model is not well calibrated), we 
determined that our observations would be exome wide significant (P < 1.25 × 10−6) even if the 
mutation rate at this position were up to eightfold higher (5.4 × 10−5) than the cumulative LoF rate 
for all other positions in SETD1A (6.6 × 10−6). If the two-base deletion mutation rate were truly this 
high (that is, greater than 99.99% of all per-gene LoF mutation rates), we would expect to find 4.9 
observations in 45,376 non-schizophrenia exomes in ExAC, but instead we observed only 1 (Fisher’s 
exact test, P = 0.044). Using a minigene construct, we further found that this two-base deletion 
resulted in the retention of the upstream intron. This was predicted to lead to the translation of 
exon 15, the subsequent intron and an out-of-frame translation of exon 16 resulting in a premature 
stop codon (Supplementary Fig. 11 and Online Methods). Finally, if we ignored the de novo status of 
variants in our discovery and  replication data sets and used ExAC exomes as additional controls 
(Online Methods and Table 2), LoF variants in SETD1A were significantly associated with 
schizophrenia using a basic test of case-control burden (P = 2.6 × 10−8, OR 37.6, 95% CI 8.0–353). 
Taken together, these analyses exclude many possible artifacts and provide confidence in our 
conclusion that LoF variants in SETD1A confer substantial risk for schizophrenia. 
SETD1A is associated with severe developmental disorders All heterozygous carriers of SETD1A LoF 
variants satisfied the full diagnostic criteria for schizophrenia, including classic positive symptoms 
such as hallucinations, prominent disorganization and paranoid delusions (Table 3). Eight patients 
had evidence of chronic illness, requiring long-term psychiatric services. Notably, of the seven 
SETD1A LoF carriers for whom any information on intellectual functioning was available, one was 
noted to have severe learning  difficulties and the other six appeared to have mild to moderate 
learning difficulties. Four patients were noted to have achieved developmental milestones with 
clinically salient delays (Table 3). We were unable to confirm whether the three Swedish carriers had 
any form of cognitive impairment. This is consistent with previous reports that individuals with 
autism or schizophrenia who have de novo LoF mutations have a higher rate of cognitive 
impairment12,25. 
To investigate whether SETD1A might be involved in other neurodevelopmental disorders, we 
looked for de novo LoF mutations in SETD1A in 3,581 published trios with autism, severe 
developmental disorders (DD) and/or intellectual disability15,26–28, but found none. We next 
turned to an additional 3,148 children with diverse, severe, developmental disorders recruited as 
part of the Deciphering Developmental Disorders (DDD) study, and discovered four probands with 
LoF variants in SETD1A (Table 4). Three of these were the recur-rent exon 16 splice junction indel 
described above (two de novo, one maternally inherited) and the fourth was a maternally inherited 
frameshift insertion (Fig. 2). We validated all four LoF variants using Sanger sequencing. All four 
probands had developmental delay with additional phenotypes that clustered in the larger DDD 
study (empirical P = 0.042; Online Methods). A fifth proband was found to have a de novo 650-kb 
deletion that encompassed SETD1A as well as 29 other genes (Supplementary Fig. 12 and Online 
Methods). SETD1A did not reach exome-wide significance as a developmental disorder gene in the 
DDD study alone (P = 3.0 × 10−3), but when we jointly analyzed all samples, the association was clear 
to both severe developmental disorders and schizophrenia (P = 3.1 × 10−8; Table 1). Because all of 
the DDD SETD1A carriers were under 12 years of age at recruitment and schizophrenia rarely 
manifests at this age29, it remains unknown whether these individuals will develop schizophrenia. 
In 5,720 unrelated Finnish individuals exome sequenced as part of the Sequencing Initiative Suomi 
project (Online Methods), we identified two additional heterozygous LoF variants in SETD1A. One 
individual with a stop-gain variant was recruited as part of the Northern Finnish Intellectual Disability 
(NFID) cohort with a diagnosis of mental retardation, short stature, mild facial dysmorphology and 
EEG abnormalities (Table 4). Notably, this individual was also diagnosed with delusional disorder and 
unspecified psychosis at 15 years of age. The second SETD1A LoF carrier belonged to the Northern 
Finnish 1966 Birth Cohort (NFBC), a representative, geographically based population cohort. This 
individual had epileptic episodes at 7 years of age and was diagnosed with an unspecified 
personality disorder by a psychiatrist. Thus, in an additional search for SETD1A LoF carriers, only two 
were found, both in individuals affected by neuropsychiatric disorders. 
De novo burden in neurodevelopmental disorders 
Even though our study had an overall sample size comparable to those of recent ASD and DD studies 
that identified 7 ASD genes and 32 DD genes15,26, we were only able to implicate a single 
schizophrenia gene at genome-wide significance. To investigate this further, we aggregated de novo 
mutations identified in 2,297 ASD, 1,113 DD and 566 control trios with our 1,077 schizophrenia trios 
and compared the rates of de novo events in each group relative to baseline exome-wide mutation 
rates (Online Methods). The rates of de novo mutations across damaging missense and LoF variants 
were significantly higher in DD than in ASD, and higher in ASD than in schizophrenia (Fig. 3).  Indeed, 
the rate of damaging missense variants in schizophrenia was not different from baseline rates (P = 
0.45) and only nominally higher than in controls (P = 0.029), and the rates of LoF variants were only 
slightly elevated (P = 5.7 × 10−3). In ASD, by contrast, missense (P = 9.4 × 10−10) and LoF (P = 3.7 × 
10−15) rates were significantly greater than expectation. In developmental disorders, the rates were 
even higher (missense: P = 2.5 × 10−17; LoF: P = 1.3 × 10−31) (Fig. 3). 
 
 
 
  
 
Figure 2 The genomic position and coding consequences of 16 SETD1A LoF variants observed in the 
schizophrenia exome meta-analysis, the DDD study and the SiSU project. Variants discovered in 
patients with schizophrenia are plotted above the gene and those discovered in individuals with 
other neurodevelopmental disorders (from DDD and SISu) are plotted below. Each variant is colored 
according to its mode of inheritance. All LoF variants appeared before the conserved SET domain, 
which is responsible for catalyzing methylation. Seven LoF variants occurred at the same two-base 
deletion at the exon 16 splice acceptor (c.4582-2delAG>-). 
 
Across all genes in the genome, the rate of disruptive de novo variants differed markedly across 
these disorders. Because the recurrence of de novo mutations is a particularly powerful way to 
identify risk genes, the weak excess of de novo variants in schizophrenia provides at least a partial 
explanation for the limited success of this strategy to date in identifying genes for this disorder. 
DISCUSSION 
We identified an association between rare LoF variants in SETD1A and risk of schizophrenia and 
other severe neurodevelopmental phenotypes. A previous report13 suggested SETD1A as a 
candidate schizophrenia gene on the basis of two of the de novo mutations included in our analysis. 
Our study establishes the SETD1A association at a significance exceeding a Bonferroni corrected P 
value of 1.25 × 10−6 independent of any specification of gene mutation rate. Indeed, in keeping with 
observations in other neurodevelopmental disorder sequencing studies, even larger meta-analyses 
of schizophrenia exomes will be required to define the phenotypic spectrum of SETD1A LoF variant 
carriers, to rule other candidates in or out, and to identify new risk genes. 
SETD1A, also known as KMT2F, encodes one of the methyltransferases that catalyze the methylation 
of lysine residues in histone H3. 
 
Figure 3 A comparison of genome-wide de novo mutation rates in probands with ASD, DD, 
schizophrenia (SCZ) and controls. Rates are modeled using calibrated genome-wide mutation rates. 
Significant excess of de novo mutations when compared to the baseline model, *P < 4 × 10−3 
(Bonferroni correction for 12 tests). Nominal significance can be inferred from the error bars (95% 
CI). Mis15, damaging missense; Syn, synonymous; see Online Methods. 
 
A R T I C L E S 
Loss-of-function variants in at least five other genes in this family result in dominant Mendelian 
disorders characterized by severe developmental phenotypes, including intellectual disability30. 
These include Wiedemann-Steiner syndrome (KMT2A), Kleefstra syndrome (EHMT1) and Kabuki 
syndrome (KMT2D) (Supplementary Fig. 13). Moreover, rare de novo LoF mutations and copy 
number variants in KMT2C, KMT2E, KDM5B and KDM6B have been recently associated with autism 
risk16. The developmental and cognitive phenotypes of SETD1A carriers are consistent with these 
other Mendelian conditions of epigenetic machinery; however, among all genes associated with 
developmental disorders and intellectual disability, SETD1A is the first shown to definitively 
predispose to schizophrenia, offering insights into the biological differences underlying these 
conditions26,31.  As with other risk genes for severe neurodevelopmental phenotypes, it is possible 
that an allelic series of LoF variants exists in SETD1A, where different variants increase risk for 
different clinical features. However, seven of the 16 LoF variant carriers (Fig. 2) have the same two 
base deletion at the splice acceptor of exon-16 (c.4582-2delAG>-): four in individuals with 
schizophrenia and three in individuals diagnosed with other developmental disorders. Thus, the 
same variant is associated with both schizophrenia and developmental disorders. 
Detailed phenotypes from the DDD and SISu studies suggest that SETD1A carriers may have 
distinctive features, including delayed speech and language development, epilepsy, personality 
disorder and facial dysmorphology (Table 4). Although cognitive and developmental phenotypes in 
our schizophrenia patients were sparser, four individuals had delayed developmental milestones, 
one was noted as having mild facial dysmorphology and minimal brain dam-age and another had 
epileptic seizures during childhood (Table 3). However, impairment of cognitive function is now 
generally regarded, along with positive and negative symptoms, as an integral feature of 
schizophrenia rather than a co-morbidity, and our study, as designed, cannot address whether 
variants in SETD1A are specifically associated with the cognitive features of the disorder. Indeed, it 
would require a re-sequencing study with detailed cognitive measurements on tens of thousands of 
patients (Online Methods and Supplementary Fig. 14) to decisively answer this question. 
The clinical heterogeneity observed in carriers of SETD1A LoF variants is reminiscent of at least 11 
large copy number variant syndromes which cause schizophrenia in addition to many other 
developmental defects10,32. A canonical example is the 22q11.2 deletion syndrome, which is 
characterized by schizophrenia in 22.6% of adult carriers33, highly variable intellectual 
impairment34 and numerous severe neurological and physical defects35. A considerably larger 
cohort (such as the hundreds of cases of 22q11.2 deletion syndrome studied to date) will be needed 
to accurately estimate the relative penetrance of SETD1A LoF variants for schizophrenia, 
developmental disorders and other clinical features. 
Although disruptions of SETD1A are very rare events and occur in only a small fraction of 
schizophrenia cases (0.13% in our meta-analysis, 95% CI 0.062–0.24%), several lines of evidence 
suggest that histone H3 methylation is more broadly relevant to schizophrenia. The H3K4 
methylation gene ontology category (GO:51568) showed the strongest statistical enrichment among 
4,939 biological pathways in GWAS data of psychiatric disorders14. This category contains 20 genes, 
including SETD1A and six others (ASH2L, CXXC1, RBBP5, WDR5, DPY30 and WDR82)36–38 that 
together form the SET1-COMPASS complex, through which SETD1A regulates transcription by 
targeted methylation. Indeed, two of the genes in GO:51568 (WDR82 and KMT2E) are near genome-
wide significant associations to schizophrenia6.  A previous study of de novo CNVs in schizophrenia 
trios identified one deletion and one duplication overlapping EHMT1, another his-tone 
methyltransferase9 that has been implicated in developmental delay and a range of congenital 
abnormalities39. Finally, conserved H3K4me3 peaks identified in prefrontal cortical neurons 
colocalize with genes related to biological mechanisms in schizophrenia, including glutamatergic and 
dopaminergic signaling40. Our implication of SETD1A therefore contributes to the growing body of 
evidence that chromatin modification, specifically histone H3 methylation, is an important 
mechanism in the pathogenesis of schizophrenia. 
METHODS 
Methods and any associated references are available in the online version of the paper. 
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ONLINE METHODS 
Sample collections. Individuals clinically diagnosed with schizophrenia were recruited and exome 
sequenced as part of eight neurodevelopmental collections (Aberdeen, Collier, Edinburgh, Gurling, 
Muir, UK-SCZ, Finnish-SCZ and Kuusamo) in the UK10K sequencing project. Matched population 
controls were selected from non-psychiatric arms of the UK10K project, healthy blood donors from 
the INTERVAL project, and five Finnish population studies (ENGAGE, Familial dyslipidemia, FINRISK, 
Health 2000 and METSIM). Additional details on the UK10K data set are described in Supplementary 
Tables 3 and 4, and the sequence data were deposited into the European Genome-phenome Archive 
(EGA) under study accession code EGAO00000000079. The Swedish schizophrenia case-control study 
had been described in an earlier publication11, and we acquired processed VCFs for this data set via 
dbGaP authorized access (accession code: phs000473.v1.p1). The Deciphering Developmental 
Disorders study data set included 4,281 children with severe, undiagnosed developmental disorders. 
Probands and their parents were exome-sequenced in the project in order to identify novel genes 
associated with developmental disorders. Patient recruitment, sample collection, sequencing 
production, and initial analysis of the data set were described in detail in a previous publication26. 
The sequence data were deposited into the EGA under study accession EGAS00001000775. 
The Sequencing Initiative Suomi project is an international collaboration generating whole genome 
and whole exome sequence data from Finnish samples, and consists of a number of prospective and 
case-control cohorts, including the ENGAGE, FINRISK, Health 2000 and METSIM studies 
(http://www.sisuproject. fi/content/cohorts). The Northern Finnish 1966 Birth Cohort (NFBC) is a 
geo-graphically based representative birth cohort including 96% (N = 12,068) of all live births in the 
two most northern provinces of Finland in 1966. The NFBC began with collection of prenatal 
information and continued with follow-ups at multiple time points resulting in a rich phenotype 
database of the study participants that combines information from hospital records, official 
registers, questionnaires and clinical examinations of the participants. DNA was collected from the 
study participants during the 31-year follow up and extracted from peripheral blood using standard 
protocols. All study participants provided a written informed con-sent to participate in the study. 
The ethical review board of the faculty of medicine, University of Oulu, approved the study. The 
Northern Finnish Intellectual Disability Cohort (NFID) is an ongoing sample collection of individuals 
who have been diagnosed with ICD-10 diagnosis of intellectual disability or specific developmental 
disorder of speech and language of unknown etiology (ICD-10 codes: F70-F79 and F80-F89). The 
patients were recruited from the Northern Ostrobothnia Hospital District in Finland, including the 
Oulu University Hospital Policlinic of Medical Genetics and Tahkokangas Care Home for Disabled. 
Patients were identified through hospital records and during routine visit to the policlinic and were 
initially contacted by a trained research nurse or by their treating physician. All research subjects 
and their legal guardians provided a written informed consent to participate in the study. The 
current sample includes 324 patients and their first-degree family members (N = 631, 92 full trios) 
with GWAS and WES data available. DNA samples of the participants were extracted primarily from 
peripheral blood. In few sporadic cases where a blood sample could not be obtained, DNA was 
extracted from saliva. The ethical committees of the Northern Ostrobothnia Hospital District and the 
Hospital District of Helsinki and Uusimaa reviewed and approved the study. 
Informed consent was obtained for all samples. Further information is avail-able at 
http://www.uk10k.org/, http://www.ddduk.org, http://www.intervalstudy. org.uk/ and 
http://www.sisuproject.fi/. 
Sequence data production. 1–3 µg of DNA was sheared to ~100–400 bp using either a Covaris E210 
or LE220 machine (Covaris) and processed using Illumina paired-end DNA library preparation. The 
DNA was enriched using the Agilent SureSelect Human All Exon v.3 or v.5 kits. All libraries were 
sequenced on the Illumina HiSeq 2000 with 75 base paired-end reads in multiple batches accord-ing 
to the manufacturer’s protocol. Sequencing reads that failed quality control (QC) were first removed 
using the Illumina GA pipeline. Remaining raw reads were mapped to the reference genome (UK10K: 
GRCh37, INTERVAL: GRCh37_hs37d5) using BWA (v0.5)41 and duplicate fragments were marked 
using Picard (UK10K: v1.36, INTERVAL: v1.114)42. We used GATK (UK10K: v1.1-5; INTERVAL: v3.2-2) 
to perform local realignment around indels and recalibrate base qualities in each sample BAM43. All 
samples were individually called using GATK Haplotype Caller (v3.2), merged into batches of 200 
samples using CombineVCFs, and joint-called using GenotypeVCFs, all at default settings44,45. 
Supplementary Figure 1 showed that the samples enriched using the v.5 kit have lower read depth 
across the entire exome, but cover a much larger percentage of coding regions than in any previous 
capture. The samples in the UK10K project are divided into two batches, clearly reflecting a 
chemistry change that occurred early in the project. The DDD study exomes more closely resembled 
the UK10K v.3 samples but clear differences in coverage exist between the v.3 and custom v.3 
capture. Due to different captures used in the UK10K and INTERVAL data sets, variant calling was 
performed at the union of the Agilent v.3 and v.5 captures with 100 base pairs of flanking sequence. 
To harmonize variant calls across all sequencing batches, we limited subsequent QC and analysis to  
variants covered at 7× or more in at least 80% of samples in each sequencing batch (Supplementary 
Fig. 1). 
Sample-level quality control. Quality control was performed on each population (UK, Finnish and 
Swedish) separately. We removed samples with a contamination fraction ≥3% estimated using 
VerifyBamID (v1.0)46 or low coverage (≤75% of the Gencode v.19 coding region covered at ≥10×). 
Principal components analysis (PCA) was performed using PLINK v1.9 (ref. 47) on a set of high-quality 
(VQSR tranche 99.0%, missingness < 3% and Hardy-Weinberg P < 10−3), LD-pruned (r2 > 0.2), 
common (MAF > 5%) SNPs found in our exome capture and in 1000 Genomes Project Phase III data. 
Ten principal components were estimated using 1000 Genomes samples, onto which we projected 
all of our cases and controls (Supplementary Fig. 5). We verified whether samples had the same 
population ancestry (UK, Finnish or Swedish) as reported in the sample manifests and excluded 
individuals who were of non-European ancestry. We estimated kinship coefficients between each 
sample pair using KING v1.4 (ref. 48) and excluded one member of any apparent relative pair 
(kinship ≥ 0.09375). After sample QC, 6,122 UK samples (1,353 cases and 4,769 controls), 2,412 
Finnish samples (392 cases and 2,020 controls) and 5,073 Swedish samples (2,519 cases and 2,554 
controls) were available for analysis. 
Variant-level quality control and annotation. We empirically derived thresholds for site and 
genotype filters that balanced sensitivity and specificity by training on the following: ExomeChip 
genotype calls in 295 UK10K cases and doubleton inherited variants (truth sets) and singleton 
Mendelian inheritance inconsistencies (false set) in 227 trios of the DDD study. We kept SNPs in the 
VQSR tranche with 99.75% sensitivity and with mean genotype quality (GQ) ≥ 30. Individual 
genotypes were retained if they had a GQ ≥ 30, alternate allele read depth (DP1) 2, allelic balance 
(AB) ≥ 0.2, and AB ≤ 0.8. Using these thresholds, we removed 95.63% of Mendelian errors while 
retaining 98.38% of doubleton inherited variants and 99.62% of heterozygous Exomechip SNPs. We 
kept indels in the VQSR tranche with 99.50% sensitivity and with mean GQ ≥ 90. Individual 
genotypes were retained if they had GQ ≥ 90, DP1 ≥ 2, AB ≥ 0.25, and AB ≤ 0.8. Using these 
thresholds, we removed 92.35% of all indel Mendelian errors and retained 93.60% of all doubleton 
inherited indels. We further excluded SNPs and indels with missingness > 20%, Hardy-Weinberg 
equilibrium χ2 P < 10−8, variants within low-complexity regions49 and indels with more than two 
alternate alleles or within three base pairs of another indel. 
Following sample and variant QC, the per-sample transition-to-transversion ratio was comparable 
between all populations (mean ~3.25) (Supplementary  Fig. 4). We still observed differences in total 
variant counts among the UK, Finnish and Swedish collections (Supplementary Fig. 3), likely 
reflecting differences in sequencing depth, capture reagents, sequencing protocol, read alignment 
and variant calling. However, variant counts and population genetics metrics were consistent 
between cases and controls within each population group. 
We used the Ensembl Variant Effect Predictor (VEP) version 75 to annotate all variants according to 
Gencode v.19 coding transcripts50. We grouped frameshift, stop gained, splice acceptor and donor 
variants as loss-of-function (LoF), and missense or initiator codon variants with a CADD Phred score ≥ 
15 as  damaging missense51. 
Statistical significance and robustness of rare variant association analyses. Previous large sequencing 
analyses such as the Swedish schizophrenia, DDD and NHLBI myocardial infarction studies11,26,52 
have defined genome-wide significance for gene burden tests using a Bonferroni correction for the 
number of genes and the number of functional and frequency cut-offs tested. For example, P < 1.25 
× 10−6 is 0.05 corrected for 20,000 genes tested for nonsynonymous and LoF variants, and a further 
correction for two frequency thresholds would require the even more stringent cutoff of P < 6.25 × 
10−7. 
For these thresholds to control false positives, however, the test being used must produce well-
calibrated P values. This has been shown to be true for standard approaches in a case-control 
setting, such as the basic burden test, Fisher’s exact test and the sequence kernel association test 
(SKAT)53, as long as the cases and controls are well-matched and residual differences are corrected 
for11,52. On the other hand, parent proband trio studies use a Poisson or Binomial model 
parameterized by gene-specific mutation rates and the discovery sample size to test for an elevated 
rate of de novo mutations. While this approach is powerful, it is less robust than the approaches 
described above. First, de novo test statistics are highly sensitive to the specification of gene-specific 
mutation rates, which are well established for SNVs but not small indels. Furthermore, the low 
counts in de novo studies make results sensitive to the size of the discovery data set. 
In previous studies of schizophrenia trios, thirty-eight genes had two or more de novo 
nonsynonymous mutations, two of which (SETD1A, P = 2.4 × 10−6 and TAF13, P = 1 ×10−6) were 
significant enough to be suggested as candidate schizophrenia genes12,13. These two findings 
illustrate the challenges of interpreting de novo data in small numbers of samples. TAF13 has a 
coding length of 375 base pairs, making just two observations significant, though no additional 
evidence has been found in subsequent, much larger studies, including our own. For SETD1A, both 
mutations are indels, making it hard to accurately calculate Poisson P values (indeed, we have 
observed one of these de novo three additional times, suggesting it has a high mutation rate). 
Furthermore, this result is no longer significant when meta-analyzed with the published 
schizophrenia de novo data sets discussed in the same study17,19, which would be the statistically 
strongest analysis available at the time. Thus, in keeping with observations in other 
neurodevelopmental disorder sequencing studies, very large meta-analyses of both case-control and  
de novo variation from schizophrenia exomes are required to exclude many possible artifacts, rule 
other candidates in or out, and identify new risk genes. 
Case-control analysis. To identify genes with a significant burden of rare, damaging variants, we 
applied the basic burden test, Fisher’s exact test and the sequence kernel association test (SKAT) as 
implemented in PLINK/SEQ53,54. For each gene, we tested LoF variants and LoF combined with 
damaging missense variants. To evaluate significance, we performed 2 million case-control permuta-
tions within each population (UK, Finnish and Swedish) to control for ancestry and batch-specific 
differences. One-sided basic burden and Fisher’s exact tests were applied at three different minor 
allele frequency (MAF) thresholds (singletons, MAF ≤ 0.1% and MAF ≤ 0.5%). We used default 
parameters for SKAT (MAF ≤ 5%) and included the first ten principal components as covariates. 
Consistent with well-matched cases and controls, we observed no genome-wide inflation in either 
common or rare variant tests (Supplementary Fig. 7). 
Gene set enrichment analyses broadly followed the methodology described in ref. 11 and 
implemented in PLINK/SEQ and the SMP utility. The gene set enrichment statistic was calculated as 
the sum of single gene burden test-statistics corrected for exome-wide differences between cases 
and controls. Statistical significance was determined through permutation testing as described 
above. We adopted the min-P procedure to empirically correct for multiple testing: the same order 
of phenotypic permutations was applied for all tests, and a joint null distribution of minimal P values 
was generated to determine the significance of each gene set. The reported odds ratios and 
confidence intervals from the gene set enrichment analyses were calculated from raw counts 
without taking into account ancestry and batch-specific differences in cases and controls. 
Meta-analysis of de novo mutations and case-control burden. Validated de novo mutations 
identified in seven published studies of schizophrenia trios were aggregated for analysis with our 
case-control cohort (Supplementary Table 1).  Recurrence of de novo mutations was modeled as the 
Poisson probability of observing N or more de novo variants in a gene given a baseline gene-specific 
mutation rate obtained from the method described in ref. 56 modified to produce LoF and damaging 
missense rates for each canonical Gencode v.19 gene55. The gene-specific mutation rates in our 
models have been validated as highly reliable in a previous publication56 and subsequently used in 
the main analyses of large-scale exome sequencing of neurodevelopmental disorders with highly 
replicable results15,26. A one-sided Fisher’s exact test was used to model the difference in rare LoF 
(MAF < 0.1%) burden between cases and controls. Subsequently, de novo and case-control burden 
P-values were meta-analyzed using Fisher’s combined probability method with df = 4 
(Supplementary Figs. 8 and 9 and Supplementary Table 2). The odds ratios reported were corrected 
using penalized maximum likelihood logistic regression model (Firth’s method, implemented in the 
logistf R package). 
We also applied the Transmission and Disequilibrium Association (TADA) method as described in ref. 
22 and implemented in ref. 15. Information from the recurrence of de novo mutations was 
integrated with inherited and case-control burden in a single statistical test. The robustness of 
results from TADA depends heavily on the specification of its hyperparameters, which are 
dependent on the (unknown) genetic architecture of the trait. These include the relative risks for de 
novo and case-control variants (parameterized by γd and γ) and the number of true risk genes in 
schizophrenia (k). Using estimates from the autism analysis would be incorrect; autism, for instance, 
has a greater excess of de novo LoF and missense mutations than schizophrenia (Fig. 3).  To ensure 
any results from TADA are robust, we ran the model across a grid of reasonable parameters: 
 γ d ∈{2,4,6,8,10,12,15,20} for LoF variants 
γ ∈{1,2,4} for LoF inherited and case-control variants 
γ d ∈{1,2,4} for missense variants 
γ = 1 for missense inherited and case-control variants 
k ∈{100,500,1000,2000} 
We used the default values for the remaining parameters and applied the following restrictions: γd > 
γ and γ lof > γmis. 
After exhaustively generating Bayes factor across a set of reasonable hyper-parameters, the results 
largely agreed with the results obtained from the Fisher’s combined probability method: only one 
gene, SETD1A, had reached genome-wide significance (Supplementary Fig. 8). We found that our 
signal in SETD1A had a q-value < 0.01 as long γd > 4, γ > 4 and k > 100. If we assumed a greater mean 
relative risk for LoF variants in SETD1A (γd > 8 and γ > 8) as expected for risk alleles in a constrained 
gene, SETD1A was exome-wide significant for any reasonable specification of k. We found that our 
signal in SETD1A is robust across frequentist and Bayesian models, under reasonable assumptions 
about schizophrenia’s genetic architecture (Supplementary Fig. 8). No other gene had a q-value 
<0.01 under any tested parameterization, including the parameterization used in the previous 
autism meta-analysis (Supplementary Table 5). 
SETD1A LoF variants in the ExAC database. We looked in the ExAC database (v0.3) for the LoF 
variants in SETD1A. All exomes were joint-called using the GATK v3.2 pipeline, and included other 
public exome data sets, such as the 1000 Genomes Project and NHLBI-GO Exome Sequencing 
Project, with additional quality control compared to their original releases. In 60,706 unrelated 
exomes, we observed seven LoF variants in SETD1A. Since the v0.3 release included the Swedish 
schizophrenia study, we excluded all samples from this data set, leaving only four LoF variants in 
45,376 exomes without a known neuropsychiatric diagnosis. We next applied the same stringent QC 
metrics we used in our analysis to ExAC data. We found that the 16:30976302-GC/G indel observed 
in two individuals was located at the same position as a high-quality SNP and occurred at a 
homopolymer run of cytosines. At the genotype level, both calls had a genotype quality (GQ) phred 
probability of < 40, far lower than used in our study in which we required indels to have a GQ > 90. 
In addition, the variant has poor allelic balance (AB < 0.15), and the BAM alignment reflected these 
low-quality metrics24. Given this evidence, we excluded the putative indel. Two high-quality SETD1A 
LoF variants in 45,376 unaffected ExAC exomes remained. 
Following the approach in ref. 56, we determined the significance of the depletion of SETD1A LoF 
variants in ExAC using a signed Z-score of the chi-squared deviation between observed and expected 
counts. We scaled the expected LoF counts provided by ExAC (43 in 60,706) to 45,376 exomes 
(expected value 32.5), and calculated the one-tailed P-value of the signed Z-score assuming two 
observed LoF variants. The degree of constraint relative to other coding genes was based on the pLI 
score24. 
If we disregarded de novo status of our variants, our combined schizophrenia data set was 
composed of 7,776 cases and 13,028 controls. After including unaffected ExAC exomes as additional 
controls, we observed ten LoF variants in 7,776 cases and two LoF variants in 58,404 controls, which 
was significantly different by a Fisher’s exact test. This result was driven by ten very rare variants in 
our schizophrenia cases: six observed in only one individual each and the seventh observed in four 
individuals. Two of these four were de novo and the other two were found in unrelated individuals 
of different ancestry (one from Sweden and one from the UK). Similarly, of the two LoF variants in 
ExAC, one was observed in only one individual and the other was the recurrent indel in an individual 
of African ancestry. Thus, our burden test of very rare variants in SETD1A would not be confounded 
by systematic differences between subpopulations in the ExAC exomes and our data set. 
Validation of SETD1A variants. We designed primers using Primer3 to produce products between 
400 and 600 bp in length centered on the site of interest. Using genomic DNA from all trio members 
as templates, PCR reactions were carried out using Thermo-Start Taq DNA Polymerase (Thermo 
Scientific), following the manufacturer’s protocol, and successful PCR products were capillary 
sequenced. Traces from all trio members were aligned, viewed, and scored for the presence or 
absence of the variant. 
Functional consequence of the exon 16 splice acceptor deletion. To assess the impact of the exon 16 
splice acceptor site variant, we created a custom minigene construct. We cloned the entire 696-bp 
genomic region encompassing exons 15, 16, 17 and intervening introns of human SETD1A, fused in-
frame to a C-terminal GFP. The entire cassette was flanked by a strong upstream promoter and a 
down-stream polyadenylation sequence. Plasmids containing either reference or deletion-containing 
forms were transfected into HELA cells, which were then grown for 2 d under standard conditions. 
RNA was extracted (RNEasy, Qiagen) from the transfected cells and used to synthesize cDNA 
(SuperscriptIII, Invitrogen). We designed minigenespecific primers to avoid amplification of 
endogenous HELA derived transcripts. The first pair of primers spanned all three exons, thus 
allowing us to detect overall splicing changes (Pair 1, Forward 2: TCGAAG AGTCATAAACACTGCCATG, 
Reverse 9: GTGAACAGCTCCTCGCCCTTG). We also designed pairs of exonic, intron-spanning primers 
to distinguish splic-ing events upstream (Pair 2, Forward 1: TTTGCAGGATCCCATCGAAGAG TC, exon 
16 reverse: CACTGTCCATGATGGCGGAGGTA) and downstream (Pair 3, exon16 forward: 
CTGCTGAGCGCCATCGGTAC, exon17 reverse: CTGAACTTGTGGCCGTTTACGTC) of exon 16. PCRs were 
performed on cDNA from two transfection replicates of each sample. Agarose gels identified PCR 
product size differences (DNA ladder: 2-log ladder, New England BioLabs), which were further 
analyzed by capillary sequencing. 
As expected, strong GFP expression was detected from the reference sequence construct. This 
suggested correct splicing between exons, leading to in-frame GFP translation. The mutant form 
displayed dramatically weaker GFP expression. mRNA was extracted from the transfected cells, and 
PCRs spanning all three exons revealed an increased transcript size in the mutant form compared to 
refer-ence (Supplementary Fig. 11a). A PCR spanning just the first 2 exons (15/16) revealed a similar 
shift in size, suggesting that the splice site deletion/mutation was causing intron retention between 
exons 15 and 16 (Supplementary Fig. 11b). Sanger sequencing of the PCR products confirmed this 
aberrant splicing outcome (Supplementary Fig. 11c). The predicted translation product would 
therefore include translation of exon 15, the subsequent intron and out-of-frame translation of exon 
16, resulting in a premature stop within this exon. The downstream splicing event to exon 17 was 
not affected. These data indicate that in human cells, the recurrent indel we observe in probands 
results in a premature stop codon and a truncated SETD1A protein. 
De novo CNV deleting a single copy of SETD1A found in the DDD study. We observed a de novo CNV 
deleting 650 kilobases around SETD1A (chr16:30,964,376-31,614,891, Supplementary Fig. 12) in a 
DDD proband. CNV calling and quality control in the DDD study was described in a previous 
publication26, and the call was supported by signal from 156 probes.  The proband had global 
developmental delay, absent speech, motor delay, sleep disturbance, developmental regression, 
feeding difficulties in infancy and generalized myoclonic seizures. 
Phenotype clustering in DDD probands. Clinical geneticists systematically recorded phenotypes of 
DDD probands using the Human Phenotype Ontology (HPO)57. These terms were used to assess the 
probability that the probands shared more similar clinical phenotypes than expected by chance. 
Similarity testing used the Human Phenotype Ontology version 2013-11-30. For each pair of terms 
we determined the information content (defined as the negative logarithm of the probability of the 
terms’ usage within the DDD cohort of 4,295 probands) for the most informative common ancestor. 
The similarity of HPO terms between two individuals was estimated as the maximum information 
content (maxIC) from pairwise comparisons of the HPO terms for the two individuals. The phenotype 
similarity for a set of N probands was estimated as the sum of all the pairwise maxIC scores. A null 
distribution of similarity scores was simulated from randomly sampled sets of N probands. The P-
value was calculated as the proportion of scores greater than or equal to the observed score. 
Comparison of de novo mutation rates. This analysis aggregated and analyzed de novo mutations 
from four different studies: 1,113 probands with develop-mental disorders26, 2,297 ASD 
probands15 and 566 control probands25,58.  De novo mutations (xd) in each neurodevelopmental 
condition was modeled as  xd ~ Pois(2NtµG), where Nt is the number of trios, µG is the genome-
wide mutation rate for a particular functional class and xd is the observed number of  de novo 
mutations in Nt trios. The genome-wide mutation rate of each variant class was calculated as the 
sum of all gene-specific mutation rates in Samocha et al.56 (µsyn = 0.137, µdamaging mis = 0.165, 
µLoF = 0.043). We modeled de novo mutations in control trios to ensure that the genome-wide 
mutation rates were well calibrated. We report the probability of observing xd or more mutations in 
Nt trios given the genome-wide mutation rate. We used the Poisson exact test to determine if 
pairwise differences in de novo rates existed between control, SCZ, ASD and DD trios, and reported 
the two-sided P-values and rate ratios. Bonferroni correction was used to adjust for multiple testing. 
Power calculations to show co-morbid cognitive impairment in schizophrenia SETD1A carriers. We 
estimated the sample size required to show that LoF variants in SETD1A specifically give rise to 
decreased cognitive function beyond their effect on schizophrenia risk. We assumed that pre-morbid 
IQ in individuals diagnosed with schizophrenia followed a Gaussian distribution with mean µ0 and 
s.d. σ. We further assumed that the distribution of pre-morbid IQ in carriers of SETD1A LoF variants 
was also Gaussian, shared the same s.d. σ, but has a shifted mean µ1.  To calculate the sample size 
needed to show that µ0 and µ1 were statistically different, we performed power calculations using a 
one-sided t-test of means across a range of parameters for the effect size and frequency of SETD1A 
LoF variants. We define the following: 
 
Assuming a modest effect on cognition (d = 0.5) and that only one in 10,000 schizophrenia patients 
carries a SETD1A LoF variant, a sample size of over 100,000 individuals would be required for 50% 
power to detect the effect. If the effect on cognition was greater (d = 1) and the true frequency was 
similar to the 0.1% observed in our study, a sample size of over 10,000 individuals would have >50% 
power. 
 
 
Consortia. UK10K consortium. Richard Anney, Mohammad Ayub, Anthony Bailey, Gillian Baird, Jeff 
Barrett, Douglas Blackwood, Patrick Bolton, Gerome Breen, David Collier, Paul Cormican, Nick 
Craddock, Lucy Crooks, Sarah Curran, Petr Danecek, Richard Durbin, Louise Gallagher, Jonathan Green, 
Hugh Gurling, Richard Holt, Chris Joyce, Ann LeCouteur, Irene Lee, Jouko Lönnqvist, Shane McCarthy, 
Peter McGuffin, Andrew McIntosh, Andrew McQuillin, Alison Merikangas, Anthony Monaco, Dawn 
Muddyman, Michael O’Donovan, Michael Owen, Aarno Palotie, Jeremy Parr, Tiina Paunio, Olli 
Pietilainen, Karola Rehnström, Tarjinder Singh, David Skuse, Jim Stalker, David St. Clair, Jaana Suvisaari 
and Hywel Williams. 
DDD Study. Nadia Akawi, Saeed Al-Turki, Kirsty Ambridge, Jeffrey Barrett, Daniel Barrett, Tanya 
Bayzetinova, Nigel Carter, Stephen Clayton, Eve Coomber, Helen Firth, Tomas Fitzgerald, David 
FitzPatrick, Sebastian Gerety, Susan Gribble, Matthew Hurles, Philip Jones, Wendy Jones, Daniel King, 
Netravathi Krishnappa, Laura Mason, Jeremy McRae, Parker Michael, Anna Middleton, Ray Miller, 
Katherine Morley, Vijaya Parthiban, Elena Prigmore, Diana Rajan, Alejandro Sifrim, Tarjinder Singh, 
Adrian Tivery, Margriet van Kogelenberg and Caroline Wright. 
Swedish Schizophrenia Study. Sarah Bergen, Kimberly Chambert, Menachem Fromer, Christina M. 
Hultman, Anna K. Kähler, Steve McCarroll, Jennifer L. Moran, Shaun Purcell, Stephan Ripke, Douglas 
Ruderfer, Edward Scolnick, Pamela Sklar and Patrick F. Sullivan. 
INTERVAL study. Participants in the INTERVAL randomized controlled trial were recruited with the 
active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported 
field work and other elements of the trial. DNA extraction and genotyping was funded by the National 
Institute of Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk/) and the 
NIHR Cambridge Biomedical Research Centre (www.cambridge-brc.org.uk). The academic 
coordinating center for INTERVAL was supported by core funding from: NIHR Blood and Transplant 
Research Unit in Donor Health and Genomics, UK Medical Research Council (G0800270), British Heart 
Foundation (SP/09/002) and NIHR Research Cambridge Biomedical Research Centre. 
A complete list of the investigators and contributors to the INTERVAL trial is provided in ref. 59 and 
http://www.intervalstudy.org.uk/about-the-study/whos-involved/interval-contributors/. 
Sequencing Initiative Suomi project. The Sequencing Initiative Suomi (SISu) project is an international 
collaboration between research groups aiming to build tools for genomic medicine. These groups are 
generating whole genome and whole exome sequence data from Finnish samples and provide data 
resources for the research community. Key groups of the project are from Universities of Eastern 
Finland, Oulu and Helsinki and The Institute for Health and Welfare, Finland, Lund University, The 
Wellcome Trust Sanger Institute, University of Oxford, The Broad Institute of Harvard and MIT, 
University of Michigan, Washington University in St. Louis and University of California, Los Angeles 
(UCLA). The project is coordinated in the Institute for Molecular Medicine Finland at the University of 
Helsinki. 
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